Mast cells can be found in close proximity to peripheral nerve endings where, upon activation, they release a broad range of pro-inflammatory cytokines and chemokines. However, the precise mechanism underlying this so-called neurogenic inflammation and associated pain has remained elusive. Here we report that the mast-cell-specific receptor Mrgprb2 mediates inflammatory mechanical and thermal hyperalgesia and is required for recruitment of innate immune cells at the injury site. We also found that the neuropeptide substance P (SP), an endogenous agonist of Mrgprb2, facilitates immune cells' migration via Mrgprb2. Furthermore, SP activation of the human mast cell led to the release of multiple pro-inflammatory cytokines and chemokines via the human homolog MRGPRX2. Surprisingly, the SP-mediated inflammatory responses were independent of its canonical receptor, neurokinin-1 receptor (NK-1R). These results identify Mrgprb2/X2 as an important neuroimmune modulator and a potential target for treating inflammatory pain.
Pubmed ID: 30686732 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets Substance P pain
View all literature mentionsThis monoclonal targets IgE
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis monoclonal targets CD117
View all literature mentionsThis monoclonal targets CD8a
View all literature mentionsThis monoclonal targets CD11b
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis monoclonal targets Fc epsilon RI alpha
View all literature mentionsThis unknown targets Chicken IgG (H+L)
View all literature mentionsThis unknown targets
View all literature mentionsThis unknown targets GFP
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis monoclonal targets Substance P
View all literature mentionsThis monoclonal targets CD16/32
View all literature mentions